Sebacia

Sebacia is a U.S. based biotechnology startup founded in 2010. The company's flagship product, Sebacia Microparticles, offers a novel FDA-cleared treatment for acne, marking the latest advancement in acne treatment in two decades. Utilizing patented technology developed in collaboration with Rice University and the Wellman Center of Photomedicine at Massachusetts General Hospital, the microparticles are designed to selectively target and heat oil-producing glands, addressing a root cause of acne lesions. Sebacia aims to provide a superior alternative to conventional topical and systemic drugs for acne. The U.S. FDA's clearance for Sebacia Microparticle followed a successful pivotal study, demonstrating its clinical efficacy and safety. The company secured a $10.00M Venture Round investment on August 30, 2019, signifying confidence in its innovative approach to acne treatment. With its focus on dermatology and aesthetics, Sebacia has the potential to disrupt the acne treatment market. By leveraging its advanced technology and FDA clearance, the company stands at the forefront of revolutionizing acne treatment. More information about Sebacia Microparticles and its commercialization plans in the U.S. can be found on their website www.sebacia.com. Based in Duluth, Georgia, the company is poised to make a significant impact in the biotechnology and dermatology sectors.